In a population of 187 HER2-positive breast cancer patients treated with adjuvant trastuzumab in medical centers in Turkey, Ulas et al. reported that patients with a pretreatment NLR >2.38 had shorter disease-free survival, but their findings were non-significant (p = 0.45) (40). The gene discussed is ERBB2; the disease is breast carcinoma.